The present invention pertains, at least in part, to novel 9-substituted
minocycline compounds. These minocycline compounds can be used to treat
numerous tetracycline compound-responsive states, such as bacterial
infections and neoplasms, as well as other known applications for
minocycline and minocycline compounds in general, such as blocking
tetracycline efflux and modulation of gene expression.